Treatment
Advertisement
New research suggests that screening guidelines should be refined to account for asymptomatic brain metastases.
A recent survey provides key insights into patient experiences with MIBC treatment and diagnosis over the past decade.
The study evaluated the safety and efficacy of ruxolitinib for treating chronic graft-versus-host disease after allo-HSCT.
Learn about key barriers to urostomy positioning and how those barriers affect outcomes for patients with bladder cancer.
Martha Raymond, MA, founder of the GI Cancers Alliance, shares insights from her recent presentation on the programming.
The “United by Unique” campaign is calling for a "fundamental shift in cancer care and health systems worldwide."
It's critical for oncology nurses to understand the implications of recent research on immunotherapy for these patients.
A new study highlights how nurses can provide education, support, and guidance as part of a dietary intervention.
Access to a multidisciplinary GVHD clinic with telehealth abilities improved care for patients with acute and chronic GVHD.
The real-world study provided insights on patient counseling, prognostics, and therapeutic decision-making processes.
Survey Illuminates Variations in Use of BI-RADS Scores to Guide Supplemental Breast Cancer Screening
A survey of NPs and family physicians is revealing variations in the use of BI-RADS scores to inform supplemental testing.
The Nursing Equity Assessment Tool can help nurses systematically and efficiently screen patients for complex care needs.
Nursing Implications of the FDA Withdrawal of Sacituzumab Govitecan for Metastatic Urothelial Cancer
Learn how oncology nurses can address patient questions about the withdrawal and help them navigate the path forward.
Mobile internet management for post-prostatectomy care improved disease knowledge, mental well-being, and quality of life.
A recent study shows that fear of cancer recurrence in patients with prostate cancer has a serious impact on functionality.
Novel agents recently approved by the FDA showed promising responses when combined for treating refractory cGVHD.
The study highlights the need for improved patient education and provider communication on early symptoms of cGVHD.
Researchers used a 10-year Markov model to evaluate the cost-effectiveness of zolbetuximab plus CAPOX.
Research presented at ASH 2024 showed that adding budesonide didn’t compromise immunologic recovery and transplant ...
Pierluigi Porcu, MD, discusses the phase II Tellomak trial and how nurses can help patients manage this rare disease.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.